secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0000318154-24-000042
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen Q3 2024 revenue $8.5B (+23%), GAAP EPS $5.22 (+62%), non-GAAP EPS $5.58 (+13%)
--------------------------------------------------------------------------------

- Total revenues $8.5B (+23% YoY); product sales grew 24% on 29% volume growth.
- GAAP EPS $5.22 (+62%); non-GAAP EPS $5.58 (+13%).
- Free cash flow $3.3B vs $2.5B in Q3 2023.
- Rare disease portfolio contributed $1.2B in sales; 10 products had double-digit growth.
- Non-GAAP operating income $4.0B; operating margin 49.6% (down 2.4 ppt).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000031815424000042/0000318154-24-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000031815424000042/amgn-20241030.htm
  HTML page:      https://secwatch.observer/filing/0000318154-24-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer